| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 11.70 | 15.7% | 21.2% |
| Total Income | 11.70 | 15.7% | 21.2% |
| Expenditure | 13.96 | 5.2% | 2.0% |
| PBT | -3.99 | 41.5% | 10.9% |
| Net Profit | -4.02 | 33.5% | 13.2% |
| OPM | -19.26% | 11.95pp | 28.30pp |
| NPM | -34.36% | 4.60pp | 13.63pp |
| EPS | -0.09 | 28.6% | 18.2% |
Myomo Reports Q2 2026 Revenue of $11.7 Million, Up 21% Year-over-Year
06 Aug 2026 · 6 Aug, 1:49 am
Summary
Myomo, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $11.7 million, a 21% increase year-over-year. The company achieved a significant improvement in gross margin, expanding by 9.4 percentage points to 72.1%, and reduced its operating loss to $2.3 million from $4.6 million in the prior year. Management highlighted the positive impact of their go-to-market strategy and raised full-year revenue guidance to $45 million to $47 million, anticipating continued growth and operating leverage.
Key Highlights
- 1
Myomo reported second quarter revenue of $11.7 million, an increase of 21% year-over-year.
- 2
Revenue from the U.S. O&P and International sales channels increased by 130% and 32%, respectively, year-over-year.
- 3
Gross margin expanded by 9.4 percentage points to 72.1% in the second quarter of 2026 compared to 62.7% in the prior year.
- 4
Operating loss for the second quarter of 2026 was $2.3 million, an improvement from an operating loss of $4.6 million in the second quarter of 2025.
- 5
Adjusted EBITDA loss for the second quarter of 2026 improved to $0.8 million, compared to $4.0 million for the second quarter of 2025.
- 6
The company is raising its full year revenue guidance to $45 million to $47 million.
- 7
Myomo recorded a record 255 orders in the second quarter, an increase of 23% year over year.
Management Comments
Paul R. Gudonis
I am pleased to report that the evolution of our go-to-market approach is driving positive results. Revenue of $11.7 million exceeded our expectations, with 53% of second quarter revenues generated from referral network sources through our MyoConnect program and other sales channels. In addition, we generated operating leverage as we grew revenue 21% while holding operating expenses roughly flat. We believe our growing clinical referral network and the increased market awareness of our wearable robotics platform will lead to greater adoption by rehab clinicians and the hundreds of thousands of potential MyoPro candidates they treat. We anticipate continued progress on these initiatives and as a result are raising the revenue guidance to approximately 10-15% growth over the prior year. In the third quarter of 2026, we expect continued year-over-year revenue growth with modestly higher operating expenses on a sequential basis, as we expand our MyoConnect program. We expect third quarter 2026 revenue to be in the range of $11.5 million to $12.0 million, up 14% to 19% year-over-year. We are raising our full year revenue guidance to $45 million to $47 million. We reiterate our full year operating leverage expectation, and we expect cash burn to be less than $2 million during the second half of the year.
Informational and educational content only. Not investment advice.